Intrathecal baclofen for the treatment of tetanus

Clin Infect Dis. 2004 Feb 1;38(3):321-8. doi: 10.1086/380636. Epub 2004 Jan 7.

Abstract

Tetanus remains a serious problem in public health, particularly in developing countries, despite efficient prevention programs. A retrospective study was conducted at an infectious diseases intensive care unit during 1998-2003 involving patients admitted with grade III tetanus. The aim of the study was to evaluate the efficacy and safety of intrathecal baclofen for the treatment of tetanus. Lumbar puncture was performed, and a subarachnoid catheter was inserted for drug administration. An intrathecal bolus of baclofen was followed by a continuous infusion of 20 microg/h, until a maximum daily dose of 2 mg was provided. Twenty-two patients were treated overall. Control of the symptoms was achieved in all patients but one. Seven patients had colonization of the catheter, and 1 patient developed meningitis. All patients except one recovered. In our study, this means of treatment was efficacious and well tolerated.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Baclofen / administration & dosage
  • Baclofen / therapeutic use*
  • Female
  • Humans
  • Injections, Spinal*
  • Male
  • Middle Aged
  • Muscle Relaxants, Central / administration & dosage
  • Muscle Relaxants, Central / therapeutic use*
  • Retrospective Studies
  • Tetanus / diagnosis
  • Tetanus / drug therapy*
  • Treatment Outcome

Substances

  • Muscle Relaxants, Central
  • Baclofen